Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because the familiar routine of online calls and deadlines has, predictably, returned. But what can you do? The world keeps spinning, no matter how hard we try to slow it down. So to cope, we are firing up the coffee kettle and brewing cups of stimulation. Our choice today is salted caramel mocha — a taste of the Jersey shore. Meanwhile, here are some tidbits. Hope your day goes well and you conquer the world…

Shionogi (SGIOY) has started human trials of the first once-a-day pill for Covid-19 patients, joining Pfizer (PFE) and Merck (MRK) in the race to find treatments for the disease, The Wall Street Journal tells us. The company said the once-a-day dosing would be more convenient and began trials this month that are likely to continue until next year, but  is months behind Pfizer and Merck, which have started later-stage tests of their pills. Pfizer has said its twice-daily pill could be ready to hit the market as soon as this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment